Bioxtreme launches Dextreme 2.0 for stroke recovery

Bioxtreme has launched Dextreme 2.0, a new version of its robotic rehabilitation system for stroke and neurological patients. The system can deliver up to twice the improvement seen with standard robotic therapy in stroke recovery studies, according to the company.

The new system is designed for upper-extremity rehabilitation in people affected by stroke and other neurological conditions. Registered with the US Food and Drug Administration and CE marking system, Dextreme 2.0 combines Bioxtreme's Error Augmentation method with adaptive artificial intelligence and immersive 3D therapy.

The launch comes as rehabilitation providers look for ways to tailor therapy more closely to individual patients while increasing treatment intensity. Unlike conventional robotic systems that guide a patient's movements, Bioxtreme's approach intentionally amplifies movement errors in an effort to trigger the brain's adaptive responses.

According to Bioxtreme, the method is intended to help patients develop more accurate and functional movement patterns. The goal is to support faster motor learning and improve independence in daily activities.

System changes

Dextreme 2.0 adds features designed to broaden the number of patients who can use the system and give therapists more detailed measurement tools. These include automatic movement scaling based on a patient's functional capacity, arm support for patients with limited movement, and additional therapy activities focused on daily living.

The updated platform also includes new assessment tools that generate more detailed clinical measurements and objective performance data. Upgraded motors are intended to make robotic movement smoother, while personalised therapy playlists allow patients to complete sessions more independently with limited therapist intervention.

Integrated accessibility controls have also been added to simplify navigation and response selection through handle movements. The design is intended to reduce operational friction during sessions while keeping patients engaged in structured exercises.

Clinical evidence

Clinical studies of Error Augmentation-based rehabilitation showed up to twofold greater improvement in Fugl-Meyer scores than standard robotic therapy for people recovering from stroke, according to Bioxtreme. The Fugl-Meyer assessment is widely used to measure motor recovery after stroke, making it a recognised benchmark in neurorehabilitation research.

The company's product strategy centres on the idea that therapy should respond to each patient's deficits rather than impose a uniform movement pattern. In practice, the system adjusts support and challenge levels to the individual while collecting data clinicians can use to monitor progress.

Rehabilitation technology developers have increasingly focused on combining robotics with software-based adaptation as healthcare providers seek evidence that devices can improve outcomes rather than simply automate exercise. Systems that can document measurable progress may also appeal more to clinics under pressure to justify spending and staff time.

For stroke survivors, recovery of the arm and hand remains one of the more difficult aspects of rehabilitation. Many patients experience long-term limitations in movement, coordination and dexterity, restricting independence and complicating routine tasks such as dressing, eating and carrying objects.

Company view

Bioxtreme develops robotic systems for upper-limb and hand rehabilitation in people with neurological injuries, including stroke and other movement-affecting conditions. Its products are built around what it describes as proprietary Error Augmentation technology, which applies adaptive forces to magnify movement errors during training.

According to the company, this mechanism is intended to accelerate motor learning and improve movement accuracy. The robotic system also uses real-time data and interactive therapy tasks intended to hold a patient's attention during repeated exercises.

Ahead of the launch, Bioxtreme framed the new system as a progression of that model, with greater emphasis on accessibility and personalisation. The additions suggest the company is trying to make the platform useful across a wider range of impairment levels while reducing the amount of direct therapist input needed for each session.

"Dextreme was built on a simple but powerful idea, that the brain learns best when it is challenged to adapt," said Eyal Samuel Shachar, Chief Executive Officer, Bioxtreme.

"Rather than compensating for errors, Dextreme uses them as a therapeutic tool. By combining robotics, AI, and neuroscience, Dextreme provides clinicians with a smarter way to deliver intensive, personalized therapy while helping patients regain confidence, function, and independence," said Shachar.